(Total Views: 851)
Posted On: 01/04/2022 3:34:45 PM
Post# of 148903
Gsuk,
As we all know we are "due" some important news/results. IMO in order of importance for the future:
NASH results: Even a small positive signal showing LL is effective should hold a large promise and affect the SP. NASH market is very large and there are no drugs to speak of to compete with. Is a low-hanging, but difficult to test, condition. The data is critical (of course), if it is clean and detailed it should propel the SP and call several companies to knock at our door. Looking forward to read carefully the results.
BTD: This is a binary result, with the FDA a "phantom" binary result. A positive (designation) will obviously put wind in our sail, a negative will be bad news but, in my case, expected. This for me is a plus but not banking on it (FDA is not our best friend).
Trials in Brazil: Need numbers and more numbers !!!! We should have advanced quite a bit there (number of patients). The silence is deafening but can't be kept much more time.
I think that FDA perhaps already communicated to CYDY their decision and agree in that we should have a conference soon. A Proactive (as much as I would like to see Christine
) would be bad news as will signal that the developments are not that significant and/or negative.
Regardless, we will have news soon.
As we all know we are "due" some important news/results. IMO in order of importance for the future:
NASH results: Even a small positive signal showing LL is effective should hold a large promise and affect the SP. NASH market is very large and there are no drugs to speak of to compete with. Is a low-hanging, but difficult to test, condition. The data is critical (of course), if it is clean and detailed it should propel the SP and call several companies to knock at our door. Looking forward to read carefully the results.
BTD: This is a binary result, with the FDA a "phantom" binary result. A positive (designation) will obviously put wind in our sail, a negative will be bad news but, in my case, expected. This for me is a plus but not banking on it (FDA is not our best friend).
Trials in Brazil: Need numbers and more numbers !!!! We should have advanced quite a bit there (number of patients). The silence is deafening but can't be kept much more time.
I think that FDA perhaps already communicated to CYDY their decision and agree in that we should have a conference soon. A Proactive (as much as I would like to see Christine
) would be bad news as will signal that the developments are not that significant and/or negative. Regardless, we will have news soon.
(10)
(0)Scroll down for more posts ▼
